Study M037
Study name | Zhu HJ 2013 |
Title | Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway |
Overall design | The objective of this study was to analyze changes within methoxyindole and kynurenine (KYN) branches of tryptophan pathway to determine whether differential regulation within these branches may contribute to mechanism of variation in response to treatment. Metabolomics approach was used to characterize early biochemical changes in tryptophan pathway and correlated biochemical changes with treatment outcome. Outpatients with major depressive disorder (MDD) were randomly assigned to sertraline (sertraline treatment group; n = 35) or placebo (placebo treatment group; n = 40) in a double-blind 4-week trial; response to treatment was measured using the 17-item Hamilton Rating Scale for Depression (HAMD-17). Targeted electrochemistry based metabolomic platform (LCECA) was used to profile serum samples from MDD patients. |
Study Type | Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 > 22 |
Sample size | 75 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LCECA: Liquid chromatography electrochemical array (LCECA); MS-based; GC-MS: gas chromatography time-of-flight-mass spectrometry (GCTOF-MS) platform; |
PMID | |
DOI | |
Citation | Zhu H, Bogdanov MB, Boyle SH, et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS One 2013;8(7):e68283. |
Metabolite | L-Tryptophan; L-Methionine; L-Tyrosine; 5-Hydroxyindoleacetic acid; Hydroxyphenyllactic acid; Serotonin; Hypoxanthine; Uric acid; Delta-Tocopherol; Hydroxykynurenine; Xanthine; 5-Methoxytryptamine; Tryptophanol; |
